- Home
- LPTX vs RDIB Comparison
LPTX vs RDIB Comparison
Compare LPTX & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- RDIB
- Stock Information
- Founded
- LPTX 2011
- RDIB 1937
- Country
- LPTX United States
- RDIB United States
- Employees
- LPTX N/A
- RDIB N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- RDIB Movies/Entertainment
- Sector
- LPTX Health Care
- RDIB Consumer Discretionary
- Exchange
- LPTX Nasdaq
- RDIB Nasdaq
- Market Cap
- LPTX 119.6M
- RDIB 140.2M
- IPO Year
- LPTX N/A
- RDIB N/A
- Fundamental
- Price
- LPTX $0.33
- RDIB $10.20
- Analyst Decision
- LPTX Hold
- RDIB
- Analyst Count
- LPTX 1
- RDIB 0
- Target Price
- LPTX N/A
- RDIB N/A
- AVG Volume (30 Days)
- LPTX 3.3M
- RDIB 11.4K
- Earning Date
- LPTX 08-11-2025
- RDIB 08-13-2025
- Dividend Yield
- LPTX N/A
- RDIB N/A
- EPS Growth
- LPTX N/A
- RDIB N/A
- EPS
- LPTX N/A
- RDIB N/A
- Revenue
- LPTX N/A
- RDIB $205,644,000.00
- Revenue This Year
- LPTX N/A
- RDIB $7.47
- Revenue Next Year
- LPTX N/A
- RDIB $13.22
- P/E Ratio
- LPTX N/A
- RDIB N/A
- Revenue Growth
- LPTX N/A
- RDIB N/A
- 52 Week Low
- LPTX $0.22
- RDIB $5.78
- 52 Week High
- LPTX $4.79
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- LPTX 48.69
- RDIB 50.27
- Support Level
- LPTX $0.28
- RDIB $9.30
- Resistance Level
- LPTX $0.36
- RDIB $11.82
- Average True Range (ATR)
- LPTX 0.04
- RDIB 0.68
- MACD
- LPTX 0.01
- RDIB 0.06
- Stochastic Oscillator
- LPTX 39.43
- RDIB 44.38
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.